author-photo

Jon E. Arnason

Beth Israel Deaconess Medical Center

129

Papers

1921

Citations

Citation Trend

Filter By

Papers (76) Sort By

Journal Conference Others

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
EPR21-034: Epidemiology of Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Patients by Line of Therapy in the United States (US) and Europe (EU)

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma

2021 Journal of hematology
Show All
- Source
- Cite
- Save
Citations (0)
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (7)